The success of GLP-1R-targeting drugs highlights their viability as a treatment approach. Currently, there are four ...

Eli Lilly topped the list of the 20 biggest pharmas by market cap with a more than 39% improvement year-to-date in its share ...

The stocks of companies that make the new class of drugs to treat obesity and manage diabetes were higher across the board ...

The winners and losers of Biden’s plans to expand coverage of weight-loss drugs US President Joe Biden wants to expand the ...

Mounjaro is a treatment for Type 2 diabetes that activates GIP and GLP-1 pathways to help regulate blood sugar. It’s part of ...

Shares of Eli Lilly LLY and Novo Nordisk NVO were up on Tuesday, likely due to a proposal by President Biden that Medicare ...

Pharmaceutical stocks make great additions to any portfolio in any market environment. A good one promises steady revenue ...

Data from a phase II study shows that AMGN's obesity drug MariTide leads to sustainable weight loss, robust improvements in cardiometabolic parameters and strong HbA1c reduction.

It’s unclear what impact a change in presidential administration will have on the proposal to widen access for those with obesity.

William Blair's assessment is that MariTide is an improvement on current obesity therapies with a profile that "will be ...

The Biden administration has announced a new proposal to include weight-loss drugs under Medicare and Medicaid programmes.